Table 2 Antibiotic resistance profiling
Antibiotics | Zone of inhibition (mm) | ||||||
|---|---|---|---|---|---|---|---|
Gram Negative bacteria | Gram Positive bacteria | CLSI guideline | |||||
Escherichia coli | Pseudomonas aeruginosa | Staphylococcus epidermidis | Staphylococcus aureus | S | I | R | |
Cefepime | 9 | 15 | – | – | ≥ 18 | 15–17 | ≤ 14 |
Ciprofloxacin | No zone | 20 | 20 | 22 | ≥ 21 | 16–20 | ≤ 15 |
Imipenem | 20 | 18 | – | – | ≥ 23 | 20–22 | ≤ 19 |
Cefoxitin | 17 | No zone | 14 | 15 | ≥ 18 | 15–17 | ≤ 14 |
Ampicillin | No zone | No zone | 18 | No zone | ≥ 17 | 14–16 | ≤ 13 |
Aztreonam | 12 | 17 | No zone | No zone | ≥ 21 | 18–20 | ≤ 17 |
Tetracycline | 8 | No zone | No zone | 18 | ≥ 15 | 12–14 | ≤ 11 |
Ceftazidime | 10 | 14 | – | – | ≥ 21 | 18–20 | ≤ 17 |
Minocyclin | 13 | 13 | – | 18 | ≥ 19 |  | ≤ 14 |
Gentamycin | No zone | 18 | 16 | 18 | ≥ 15 | 13–14 | ≤ 12 |
Co-trimoxazole | No zone | 12 | No zone | 15 | ≥ 16 | 11–15 | ≤ 10 |
Colistin | 9 | 12 | No zone | No zone | ≥ 11 |  | ≤ 10 |
Clindamycin | No zone | No zone | No zone | No zone | ≥ 21 | 15–20 | ≤ 14 |
Vancomycin | No zone | No zone | No zone | 15 | ≥ 22 |  | ≤ 21 |
Doxicyclin | 12 | 12 | – | 18 | ≥ 16 |  | ≤ 12 |
Erythromycin | 7 | No zone | No zone | 20 | ≥ 23 | 14–22 | ≤ 13 |
Chloramphenicol | – | – | 23 | 20 | ≥ 32 | 16 | ≤ 8 |